{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:26:16Z","timestamp":1788197176129,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","issue":"5-6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vph.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T08:45:25Z","timestamp":1381913125000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clopidogrel \u201cresistance\u201d: Pre- vs post-receptor determinants"],"prefix":"10.1016","volume":"59","author":[{"given":"N.L.","family":"Hurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.B.","family":"Nooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.Y.","family":"Chirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2013.10.002_bb0440","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.10.002_bb0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the pci-cure study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.10.002_bb0015","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0020","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W): a randomised controlled trial","volume":"367","author":"Site","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.10.002_bb0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0445","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrcardio.2009.13","article-title":"Antiplatelet drug \u2018resistance\u2019. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?","volume":"6","author":"Gorog","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment","volume":"48","author":"Angiolillo","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","volume":"30","author":"Kuliczkowski","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.10.002_bb0050","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting","volume":"45","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0055","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0060","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.0510446103","article-title":"The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts","volume":"103","author":"Savi","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vph.2013.10.002_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New p2y12 inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0070","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1538-7836.2007.02656.x","article-title":"Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients","volume":"5","author":"Paniccia","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0080","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1160\/TH07-10-0647","article-title":"Residual prothrombotic status in low responder patients to clopidogrel identified by vasodilator-stimulated phosphoprotein phosphorylation (VASP) analysis?","volume":"99","author":"Morel","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0090","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1538-7836.2009.03733.x","article-title":"Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel","volume":"8","author":"Bouman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.mbc.0000164429.21040.0a","article-title":"P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose","volume":"16","author":"von Beckerath","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.vph.2013.10.002_bb0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with p2y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","article-title":"Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease","volume":"116","author":"Angiolillo","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2013.10.002_bb0110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2013.10.002_bb0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/emboj\/18.1.37","article-title":"The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and camp-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function","volume":"18","author":"Aszodi","year":"1999","journal-title":"Embo J"},{"key":"10.1016\/j.vph.2013.10.002_bb0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/BJ20050796","article-title":"Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on ser157 by protein kinase c-dependent and -independent mechanisms in thrombin-stimulated human platelets","volume":"393","author":"Wentworth","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.vph.2013.10.002_bb0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharmthera.2007.06.012","article-title":"Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?","volume":"116","author":"Chirkov","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vph.2013.10.002_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0006-2952(02)01523-X","article-title":"Endothelium-dependent and -independent relaxation and VASP serines 157\/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta","volume":"65","author":"Sch\u00e4fer","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.vph.2013.10.002_bb0145","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.RES.87.11.999","article-title":"Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide\/cGMP signaling and endothelial dysfunction","volume":"87","author":"Oelze","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2013.10.002_bb0150","doi-asserted-by":"crossref","first-page":"H2782","DOI":"10.1152\/ajpheart.00831.2006","article-title":"Restoration of impaired endothelium-dependent coronary vasodilation in failing heart: role of eNOS phosphorylation and cGMP\/cgk-i signaling","volume":"292","author":"Gill","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2362.1982.tb00686.x","article-title":"Platelets from diabetic subjects show diminished sensitivity to prostacyclin","volume":"12","author":"Betteridge","year":"1982","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.vph.2013.10.002_bb0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/jc.2004-0137","article-title":"P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes","volume":"90","author":"Matsuno","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.vph.2013.10.002_bb0165","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2006-10-050633","article-title":"Insulin-like growth factor-1 potentiates platelet activation via the IRS\/CD36PI3k alpha pathway","volume":"110","author":"Hers","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vph.2013.10.002_bb0170","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1182\/blood-2011-10-387506","article-title":"Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36","volume":"119","author":"Zhu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.vph.2013.10.002_bb0175","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood-2010-01-265561","article-title":"Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the camp\/protein kinase a signaling cascade","volume":"116","author":"Roberts","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.vph.2013.10.002_bb0180","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/00005344-199506000-00015","article-title":"Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicamp-elevating effects of prostaglandin E1","volume":"25","author":"Chirkov","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2013.10.002_bb0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.CIR.100.2.129","article-title":"Nitrate resistance in platelets from patients with stable angina pectoris","volume":"100","author":"Chirkov","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0190","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0735-1097(01)01238-4","article-title":"Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets","volume":"37","author":"Chirkov","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0195","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/oby.2009.302","article-title":"In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin","volume":"18","author":"Russo","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.vph.2013.10.002_bb0200","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1373\/clinchem.2004.047050","article-title":"Monitoring of clopidogrel action: comparison of methods","volume":"51","author":"Geiger","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.vph.2013.10.002_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH07-09-0555","article-title":"A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry","volume":"99","author":"Jakubowski","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0210","first-page":"169","article-title":"Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?","volume":"16","author":"Angiolillo","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH11-12-0876","article-title":"The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight","volume":"108","author":"Morel","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0300-8932(10)70010-5","article-title":"Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions","volume":"63","author":"Angiolillo","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0225","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo","volume":"52","author":"Erlinge","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjcard.2012.03.027","article-title":"Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction","volume":"110","author":"Kuliczkowski","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0450","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.atherosclerosis.2011.03.039","article-title":"Impaired inhibition of P2Y12 by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention","author":"El Ghannudi","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2013.10.002_bb0240","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.amjcard.2008.10.028","article-title":"Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0245","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ccd.10497","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.vph.2013.10.002_bb0250","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","article-title":"Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events","volume":"5","author":"Bonello","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0260","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0265","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ahj.2011.06.003","article-title":"Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention\u2014a case\u2013control study","volume":"162","author":"Varenhorst","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2013.10.002_bb0270","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vph.2013.10.002_bb0275","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT OACIS-7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.10.002_bb0280","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2c19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.10.002_bb0455","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0290","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0300","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.10.002_bb0305","doi-asserted-by":"crossref","first-page":"2856-2464a","DOI":"10.1093\/eurheartj\/ehs042","article-title":"Clarifying the importance of CYP2C19 and PON-1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response","volume":"33","author":"Gong","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.10.002_bb0310","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2013.10.002_bb0320","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.vph.2013.10.002_bb0325","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0330","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1538-7836.2011.04414.x","article-title":"Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel","volume":"9","author":"Fernando","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0335","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.10.002_bb0340","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0345","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2013.10.002_bb0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1742-7843.2010.00657.x","article-title":"A functional polymorphism in the P450 3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population","volume":"108","author":"He","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.vph.2013.10.002_bb0355","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0360","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/pgs.09.42","article-title":"Statin regulation of CYP3A4 and CYP3A5 expression","volume":"10","author":"Willrich","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.vph.2013.10.002_bb0460","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1161\/01.CIR.0000137956.92971.4A","article-title":"Clinical significance of the atorvastatin-clopidogrel drug-drug interaction","volume":"110","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0370","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","article-title":"Lack of evidence of a clopidogrel\u2013statin interaction in the CHARISMA trial","volume":"50","author":"Saw","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.vph.2013.10.002_bb0465","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0380","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","article-title":"Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.10.002_bb0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0143-4160(03)00170-2","article-title":"Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1","volume":"35","author":"Fox","year":"2004","journal-title":"Cell Calcium"},{"key":"10.1016\/j.vph.2013.10.002_bb0390","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3109\/09537104.2011.576284","article-title":"P2Y12 and cAMPEP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP","volume":"22","author":"Iyu","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.vph.2013.10.002_bb0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0925-4439(91)90050-J","article-title":"Altered g-protein expression and adenylate cyclase activity in platelets of non-insulin-dependent diabetic (NIDDM) male subjects","volume":"1096","author":"Livingstone","year":"1991","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.vph.2013.10.002_bb0400","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.10.002_bb0405","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.thromres.2008.04.003","article-title":"Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response","volume":"123","author":"Cuisset","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2013.10.002_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(10)60927-8","article-title":"Resistance to clopidogrel assessed by VASP phosphorylation is a negative prognostic factor in patients undergoing elective PCI for stable coronary artery disease: analysis from laboratory substudy of the Prague 8 trial","volume":"55","author":"Petr","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0415","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2009.06.007","article-title":"Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients","volume":"104","author":"Cuisset","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ccd.22248","article-title":"A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction","volume":"75","author":"Osmancik","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.vph.2013.10.002_bb0425","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2013.10.002_bb0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjcard.2009.04.015","article-title":"Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis","volume":"104","author":"Pinto Slottow","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.10.002_bb0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2010.03.008","article-title":"The cone-and-plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flowcytometric VASP assay and optical aggregometry","volume":"126","author":"van Werkum","year":"2010","journal-title":"Thromb Res"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189113001171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189113001171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T07:10:00Z","timestamp":1646809800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189113001171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":87,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1537189113001171"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2013.10.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clopidogrel \u201cresistance\u201d: Pre- vs post-receptor determinants","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2013.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}